TY - JOUR
T1 - Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells
AU - Wossning, Thomas
AU - Herzog, Sebastian
AU - Köhler, Fabian
AU - Meixlsperger, Sonja
AU - Kulathu, Yogesh
AU - Mittler, Gerhard
AU - Abe, Akihiro
AU - Fuchs, Uta
AU - Borkhardt, Arndt
AU - Jumaa, Hassan
PY - 2006/12/25
Y1 - 2006/12/25
N2 - The nonreceptor protein spleen tyrosine kinase (Syk) is a key mediator of signal transduction in a variety of cell types, including B lymphocytes. We show that deregulated Syk activity allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are then able to induce leukemia in mice. Syk-transformed pre-B cells show a characteristic pattern of tyrosine phosphorylation, increased c-Myc expression, and defective differentiation. Treatment of Syk-transformed pre-B cells with a novel Syk-specific inhibitor (R406) reduces tyrosine phosphorylation and c-Myc expression. In addition, R406 treatment removes the developmental block and allows the differentiation of the Syk-transformed pre-B cells into immature B cells. Because R406 treatment also prevents the proliferation of c-Myc-transformed pre-B cells, our data indicate that endogenous Syk kinase activity may be required for the survival of pre-B cells transformed by other oncogenes. Collectively, our data suggest that Syk is a protooncogene involved in the transformation of lymphocytes, thus making Syk a potential target for the treatment of leukemia. JEM
AB - The nonreceptor protein spleen tyrosine kinase (Syk) is a key mediator of signal transduction in a variety of cell types, including B lymphocytes. We show that deregulated Syk activity allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are then able to induce leukemia in mice. Syk-transformed pre-B cells show a characteristic pattern of tyrosine phosphorylation, increased c-Myc expression, and defective differentiation. Treatment of Syk-transformed pre-B cells with a novel Syk-specific inhibitor (R406) reduces tyrosine phosphorylation and c-Myc expression. In addition, R406 treatment removes the developmental block and allows the differentiation of the Syk-transformed pre-B cells into immature B cells. Because R406 treatment also prevents the proliferation of c-Myc-transformed pre-B cells, our data indicate that endogenous Syk kinase activity may be required for the survival of pre-B cells transformed by other oncogenes. Collectively, our data suggest that Syk is a protooncogene involved in the transformation of lymphocytes, thus making Syk a potential target for the treatment of leukemia. JEM
UR - http://www.scopus.com/inward/record.url?scp=33845907145&partnerID=8YFLogxK
U2 - 10.1084/jem.20060967
DO - 10.1084/jem.20060967
M3 - Article
C2 - 17130299
AN - SCOPUS:33845907145
SN - 0022-1007
VL - 203
SP - 2829
EP - 2840
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 13
ER -